Massachusetts Financial Services Co. MA Increases Stock Position in Sanofi (NASDAQ:SNY)

Massachusetts Financial Services Co. MA grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 4.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 155,078 shares of the company's stock after acquiring an additional 7,123 shares during the quarter. Massachusetts Financial Services Co. MA's holdings in Sanofi were worth $7,479,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Synergy Asset Management LLC bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. increased its holdings in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi in the fourth quarter worth $31,000. Sunbelt Securities Inc. lifted its holdings in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new stake in shares of Sanofi during the fourth quarter valued at $44,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on SNY. The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of "Moderate Buy" and an average target price of $62.50.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded up $1.84 during mid-day trading on Friday, reaching $51.50. 3,191,009 shares of the company traded hands, compared to its average volume of 2,324,450. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm has a market cap of $130.10 billion, a PE ratio of 20.68, a PEG ratio of 1.01 and a beta of 0.57. The company's 50 day moving average price is $54.97 and its 200-day moving average price is $52.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.